Postdoctoral Research Officer
The University of Queensland Diamantina Institute
The University of Queensland Diamantina Institute was established in 2007 as the sixth research institute of The University of Queensland. The aim of the Institute is to develop a better understanding of the molecular and cellular basis of disease, and to translate that understanding into practical outcomes for patients. Based at the Translational Research Institute (TRI) at the Princess Alexandra Hospital teaching campus in Brisbane, the Institute has almost 300 researchers and students who work closely with clinicians in the areas of cancer, immunology and genomic medicine. UQDI is the largest partner in TRI, and is building major programs in Immunology, Cancer and Genomic Medicine research, with a particular focus on research aimed at development of new treatments. Details of the research interests of academic staff may be accessed on the Institute's web site at http://www.di.uq.edu.au/research.
Using cutting-edge technology, including real-time cell cycle and cell death imaging in several three-dimensional cell culture and in vivo models, the laboratory of Prof Haass investigates the biology of tumour heterogeneity with the goal to develop novel therapeutic approaches by simultaneously targeting different melanoma subpopulations. Specific interests are (1) cell-cell and cell-matrix interactions of melanoma with its microenvironment (2) signalling pathways in melanoma, particularly with regards to identifying novel melanoma therapies and (3) the characterization of the dynamic heterogeneity of melanoma cell subpopulations.
The principal goal of the Postdoctoral Research Officer's project is to evaluate the role of MITF in the regulation of the sub-compartmentalisation of differentially cycling tumour cells in melanoma. Specifically, we will investigate the precise impact of MITF and its downstream effectors on adhesion of melanoma cells to each other, to other cell types in the tumour microenvironment and to the matrix of the tumour stroma and the consequences on differential proliferation, migration and invasion behaviour. To achieve that we will utilise live-cell high-resolution imaging of cell-cell and cell-matrix interactions and the cytoskeleton as well as real-time cell cycle and cell death imaging in 3D spheroids and in vivo.
The applicant should possess a Ph.D. or equivalent degree in molecular and cellular biology with an emphasis on cancer research and cell biology. In-depth knowledge of cancer progression on a molecular level, specifically with regards to cell-cell and cell-matrix interactions, proliferation, migration and invasion is required. Candidates with experience in these fields will be given preference. Proficiency in microscopy, cell culture, and migration/invasion assays will be necessary.
This is a full-time, fixed term appointment at Research Academic level A, for twelve months with the with possibility of extension pending funding. The remuneration package will be in the range $62,653.88 - $84,985.56 p.a., plus employer superannuation contributions of up to 17% (total package will be in the range $73,305.04 - $99,433.11 p.a.).
To discuss this role please contact Professor Nikolas Haass on +61 7 3443 7087 or firstname.lastname@example.org.
To submit an application for this role, use the Apply button below. All applicants must supply the following documents: Cover letter, Resume and Selection Criteria responses.
For information on completing the application process click here.